whatshot

VTYX   $14.0  0.14% Market Closed

Ventyx Biosciences, Inc.
show_chart Advanced Chart of VTYX
Last Events:

2023-11-07 The hottest instrument.

2023-10-09 The hottest instrument.

2023-08-09 Signal in EMA100 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Signal in Stochastic changed from bullish weakening to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2023-08-06 Signal in EMA50 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-06 Trend Power changed from to medium strength.

2023-08-05 Trend pattern changed from расходящийся треугольник to канал.

2023-08-05 Signal in MACD changed from bullish weakening to bearish reversal. Oscillator MACD is in the positive territory it crossed the signal line from the top and falls. These factors mean that the market confirms the end of the upward trend. Last signal: main and signal line crossing.

Current temperature: 1.47
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 6
Target Price Mean 13.17
Mean unverified/preliminary 13.17 / 13.17
Target Price Low / High 9.00 / 14.00
Median / STD DEV 14.00 / 2.04
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total None Sell Sell
rsi Sell Sell Sell
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 ActivelyBuy Sell Sell
ma50 Sell None None
ma100 None Sell Sell
Candlestick PatternFeb. 25, 2026 Bearish Squeeze Alert - pattern is a made up of three candlesticks. A white candlestick appears on the first day in a uptrend. The second and third days each have lower highs and higher lows than the previous day. Their color is not important. Considered to be a bearish reversal pattern.
ISIN US92332V1070
ceo Dr. Raju S. Mohan Ph.D.
Website https://ventyxbio.com
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.